Arch Med Sci 2019 Mar 4;15(2):385-392. Epub 2019 Mar 4.
Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland.
Introduction: Statins are widely used in stroke patients. The AHA/ASA guidelines recommend aggressive statin therapy in atherosclerotic stroke patients. Their beneficial effects are due to both their hypolipemic and pleiotropic properties. The aim of this study was to establish potential benefits from statin use in ischemic stroke patients with the diagnosis of atrial fibrillation (AF).
Material And Methods: Ischemic stroke patients with AF were enrolled in the study. Group I, the statin group ( = 181), consisted of patients who had been treated with statins before stroke. Group II, the non-statin group ( = 153), consisted of patients who had not received such treatment in the last year. In-hospital mortality and neurological deficit on admission and at discharge were analyzed using the National Institutes of Health Stroke Scale (NIHSS) score.
Results: Patients from the non-statin group had greater initial and discharge NIHSS scores (10 vs. 11.9, probability value < 0.05; 7.6 vs. 9.5, < 0.05 respectively). The improvement in NIHSS score was greater in the statin group (73.5% vs. 59.5%, < 0.01). In-hospital mortality was more frequent in the non-statin group (9.9% vs. 18.3%, < 0.05).
Conclusions: Despite the predominant use of statins in atherothrombotic stroke patients, we demonstrated the beneficial effects of statins in cardioembolic stroke patients. Detailed cardiovascular screening for statin therapy should be carried out in all AF patients with regard to primary and secondary stroke prevention.